VISIT CONTRACT PHARMA AT #1115

MilliporeSigma Launches New Sucrose Offering

11.14.19

For high risk applications such as injectables and biotherapeutics

John Langer of MilliporeSigma discusses the company’s new sucrose offering under the company’s EMPROVE EXPERT category for high risk applications, such as injectables and biotherapeutics.
 
MilliporeSigma developed a new filtration-based manufacturing process resulting in a new, highly purified sucrose grade with reduced levels of nanoparticle impurities (NPI). The new product, Sucrose EMPROVE EXPERT Ph Eur, ChP, JP, NF, is for the high-risk applications of manufacturing and formulating biomolecules.

As a widely used protein stabilizer for biomolecule formulation, the quality of sucrose is crucial. In an exclusive collaboration with Coriolis Pharma, MilliporeSigma designed the new purification process and associated nanoparticle analytics of sucrose. The result is a highly pure sucrose that offers the following benefits over non-purified sucrose: A low level of NPIs on the limit of detection of current technologies, reducing risk of protein stability; Less interference with analytical methods; High batch-to-batch consistency; Reduced risk of API damage.
 

John Langer, Technology Manager – Actives & Formulation, Americas
John Langer joined MilliporeSigma in April of 2019 to support the excipients portfolio focused on biopharmaceutical therapies. Before coming to MilliporeSigma, John worked as a Research Scientist for over 8 years at Lonza (Walkersville, MD) in the R&D Department. He supported advanced cell culture initiatives, ideated and developed new cellular products and applications, and served as a technical liaison for 3D cell culture applications.